UY25032A1 - PROCEDURE TO PREPARE A NEW COMPOSITION - Google Patents
PROCEDURE TO PREPARE A NEW COMPOSITIONInfo
- Publication number
- UY25032A1 UY25032A1 UY25032A UY25032A UY25032A1 UY 25032 A1 UY25032 A1 UY 25032A1 UY 25032 A UY25032 A UY 25032A UY 25032 A UY25032 A UY 25032A UY 25032 A1 UY25032 A1 UY 25032A1
- Authority
- UY
- Uruguay
- Prior art keywords
- composition
- pharmaceutically acceptable
- compound
- acceptable carrier
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención describe un procedimiento para preparar una composición farmacéutica de 5-[4-[2-(N-metil-N-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona (Compuesto (I)) en una forma farmacéuticamente aceptable y un vehículo farmacéuticamente aceptable, cuyo procedimiento comprende: (i) preparar una primera composición caracterizada porque la composición es un concentrado del Compuesto (I) en una forma farmacéuticamente aceptable adaptada para ser diluida a fin de proporcionar una composición para administración oral en dosis unitarias y un primer vehículo farmacéuticamente aceptable; (ii) mezclar la primera composición con un segundo vehículo farmacéuticamente aceptable para proporcionar la composición requerida de Compuesto (I). Se ha indicado que una dosis diaria discreta y particular de Compuesto (I) proporciona un efecto especialmente beneficioso sobre el control glicémico y, por lo tanto, es particularmente útil para el tratamiento de la diabetes mellitus.The present invention describes a process for preparing a pharmaceutical composition of 5- [4- [2- (N-methyl-N- (2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione (Compound (I) ) in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier, the process of which comprises: (i) preparing a first composition characterized in that the composition is a concentrate of Compound (I) in a pharmaceutically acceptable form adapted to be diluted in order to provide a composition for oral administration in unit doses and a first pharmaceutically acceptable carrier; (ii) mixing the first composition with a second pharmaceutically acceptable carrier to provide the required composition of Compound (I). A particular and discrete daily dose of Compound (I) has been indicated to provide an especially beneficial effect on glycemic control and is therefore particularly useful for the treatment of diabetes mellitus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9711683.4A GB9711683D0 (en) | 1997-06-05 | 1997-06-05 | Composition |
| GBGB9712851.6A GB9712851D0 (en) | 1997-06-18 | 1997-06-18 | Composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25032A1 true UY25032A1 (en) | 1998-11-26 |
Family
ID=26311662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25032A UY25032A1 (en) | 1997-06-05 | 1998-06-04 | PROCEDURE TO PREPARE A NEW COMPOSITION |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0998284A1 (en) |
| JP (1) | JP2001521553A (en) |
| KR (1) | KR20010013410A (en) |
| CN (3) | CN1112926C (en) |
| AP (1) | AP1214A (en) |
| AR (2) | AR008198A1 (en) |
| AU (1) | AU8215098A (en) |
| BG (1) | BG104048A (en) |
| BR (1) | BR9810405A (en) |
| CA (2) | CA2333352A1 (en) |
| CO (1) | CO4940400A1 (en) |
| DZ (1) | DZ2510A1 (en) |
| EA (1) | EA002384B1 (en) |
| GB (1) | GB9711683D0 (en) |
| HU (1) | HUP0004070A3 (en) |
| ID (1) | ID24264A (en) |
| IL (1) | IL133074A0 (en) |
| MX (1) | MXPA99011322A (en) |
| NO (2) | NO995938L (en) |
| NZ (2) | NZ523725A (en) |
| OA (1) | OA11306A (en) |
| PE (1) | PE78899A1 (en) |
| PL (1) | PL337201A1 (en) |
| SK (1) | SK164899A3 (en) |
| TR (2) | TR199902963T2 (en) |
| TW (1) | TW570797B (en) |
| UY (1) | UY25032A1 (en) |
| WO (1) | WO1998055122A1 (en) |
| ZA (2) | ZA9811572B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200103061T2 (en) | 1999-04-23 | 2002-05-21 | Smithkline Beecham P.L.C. | New pharmaceutical ingredient. |
| US20040248945A1 (en) | 1999-04-23 | 2004-12-09 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
| EP1173435B1 (en) * | 1999-04-23 | 2003-07-30 | SmithKline Beecham plc | Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt |
| GB0021978D0 (en) | 2000-09-07 | 2000-10-25 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
| WO2003050112A1 (en) * | 2001-12-13 | 2003-06-19 | Smithkline Beecham Plc | Toluenesulfonate hydrates of a thiazolidinedione derivative |
| GB0129876D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0129871D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0130509D0 (en) * | 2001-12-20 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| EP2270007A1 (en) * | 2006-05-09 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| US7435741B2 (en) | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| WO2015008234A1 (en) * | 2013-07-17 | 2015-01-22 | Glenmark Pharmaceuticals S.A. | Bicyclic heterocyclic compounds as ror gamma modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE186724T1 (en) * | 1987-09-04 | 1999-12-15 | Beecham Group Plc | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES |
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| WO1995021608A1 (en) * | 1994-02-10 | 1995-08-17 | Smithkline Beecham Plc | Use of insulin sensitisers for treating renal diseases |
| SK16498A3 (en) * | 1995-08-10 | 1999-03-12 | Warner Lambert Co | A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus |
| WO1997018811A1 (en) * | 1995-11-17 | 1997-05-29 | Warner-Lambert Company | A method of treating myotonic dystrophy |
| NZ314406A (en) * | 1996-03-18 | 2000-12-22 | Sankyo Co | Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles |
| WO1998002159A1 (en) * | 1996-07-12 | 1998-01-22 | Smithkline Beecham Plc | Novel treatment of leptine resistance |
-
1997
- 1997-06-05 GB GBGB9711683.4A patent/GB9711683D0/en active Pending
-
1998
- 1998-06-02 EA EA199901116A patent/EA002384B1/en not_active IP Right Cessation
- 1998-06-02 TR TR1999/02963T patent/TR199902963T2/en unknown
- 1998-06-02 ID IDW991520A patent/ID24264A/en unknown
- 1998-06-02 SK SK1648-99A patent/SK164899A3/en unknown
- 1998-06-02 AU AU82150/98A patent/AU8215098A/en not_active Abandoned
- 1998-06-02 PL PL98337201A patent/PL337201A1/en unknown
- 1998-06-02 CA CA002333352A patent/CA2333352A1/en not_active Abandoned
- 1998-06-02 IL IL13307498A patent/IL133074A0/en unknown
- 1998-06-02 WO PCT/EP1998/003478 patent/WO1998055122A1/en not_active Application Discontinuation
- 1998-06-02 KR KR19997011411A patent/KR20010013410A/en not_active Application Discontinuation
- 1998-06-02 AP APAP/P/1999/001696A patent/AP1214A/en active
- 1998-06-02 NZ NZ523725A patent/NZ523725A/en unknown
- 1998-06-02 CN CN98805686A patent/CN1112926C/en not_active Expired - Lifetime
- 1998-06-02 BR BR9810405-5A patent/BR9810405A/en not_active IP Right Cessation
- 1998-06-02 EP EP98932144A patent/EP0998284A1/en not_active Withdrawn
- 1998-06-02 HU HU0004070A patent/HUP0004070A3/en unknown
- 1998-06-02 CA CA002292629A patent/CA2292629C/en not_active Expired - Fee Related
- 1998-06-02 JP JP50158799A patent/JP2001521553A/en not_active Ceased
- 1998-06-02 CN CNA2003101199090A patent/CN1526391A/en active Pending
- 1998-06-02 MX MXPA99011322A patent/MXPA99011322A/en unknown
- 1998-06-02 TR TR2000/02790T patent/TR200002790T2/en unknown
- 1998-06-03 DZ DZ980120A patent/DZ2510A1/en active
- 1998-06-04 UY UY25032A patent/UY25032A1/en not_active IP Right Cessation
- 1998-06-04 CO CO98031614A patent/CO4940400A1/en unknown
- 1998-06-04 ZA ZA9811572A patent/ZA9811572B/en unknown
- 1998-06-04 AR ARP980102649A patent/AR008198A1/en not_active Application Discontinuation
- 1998-06-04 ZA ZA9804826A patent/ZA984826B/en unknown
- 1998-06-04 AR ARP980102650A patent/AR015120A1/en not_active Application Discontinuation
- 1998-06-05 PE PE1998000466A patent/PE78899A1/en not_active Application Discontinuation
- 1998-10-23 TW TW087117536A patent/TW570797B/en not_active IP Right Cessation
-
1999
- 1999-12-02 OA OA9900267A patent/OA11306A/en unknown
- 1999-12-03 NO NO995938A patent/NO995938L/en not_active Application Discontinuation
- 1999-12-27 BG BG104048A patent/BG104048A/en unknown
-
2001
- 2001-09-03 NZ NZ513922A patent/NZ513922A/en unknown
-
2002
- 2002-11-05 CN CN02149972A patent/CN1430959A/en active Pending
-
2004
- 2004-02-20 NO NO20040738A patent/NO20040738L/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25049A1 (en) | TREATMENT COMPOSITIONS FOR DIABETES MELLITUS | |
| UY25032A1 (en) | PROCEDURE TO PREPARE A NEW COMPOSITION | |
| AR057970A2 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MELLITUS DIABETES AND CONDITIONS ASSOCIATED WITH MELLITUS DIABETES AND PROCEDURES TO PREPARE SUCH COMPOSITIONS | |
| AP1545A (en) | Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione. | |
| BRPI0606768A2 (en) | oral dosage form comprising rosiglitazone | |
| TW200700063A (en) | Oral dosage form comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione | |
| BR0114196A (en) | Polymorphic forms of 5- [4- [2- [n-methyl-n- (2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and process for the preparation thereof. | |
| MY135973A (en) | Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative | |
| AR015894A1 (en) | USE OF 5- [4- [2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] TIAZOLIDIN-2,4-DIONA AND INSULIN FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINS SUCH COMPOUNDS | |
| UY25102A1 (en) | NEW COMPOSITION FOR THE TREATMENT OF DIABETES MELLITUS | |
| NZ515555A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
| BR0112981A (en) | Thiazolidinedione derivative tartrate salts | |
| AU2002343052A1 (en) | Rosiglitazone edisylates and their use as antidiabetics | |
| BR0111536A (en) | Thiazolidinedione salt for diabetes mellitus treatment | |
| GB0021784D0 (en) | Novel pharmaceutical | |
| AP2003002737A0 (en) | Tartrate salts of thiazolidinedione derivatives | |
| CY1107767T1 (en) | THIAZOLIDINODIONI PRODUCER AND USE OF IT AS ANTIBIOTIC | |
| NZ524933A (en) | Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition thereof | |
| BR0112982A (en) | Thiazolidinedione derivative tartrate salt | |
| EP1867343A3 (en) | Inclusion complexes of a cyclodextrin with a thiazolidine-2,4-dione | |
| BR0112983A (en) | Thiazolidinedione derivative tartrate salts | |
| NZ510672A (en) | Composition comprising 5-[4-[2-(N-Methyl-N-2-Pyridyl)Amino)-Ethoxy]Benzyl]Thiazolidine-2,4-Dione |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VENC | Patent expired |
Effective date: 20180604 |